Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
Creators
- Almendro, Vanessa1, 2, 3, 4
- Cheng, Yu-Kang5, 4
- Randles, Amanda6, 5, 4
- Itzkovitz, Shalev7, 8
- Marusyk, Andriy2, 3, 4
- Ametller, Elisabet1
- Gonzalez-Farre, Xavier1
- Muñoz, Montse1
- Russnes, Hege G.9, 10, 11
- Helland, Åslaug10, 9, 11
- Rye, Inga H.10, 11
- Borresen-Dale, Anne-Lise10, 11
- Maruyama, Reo2, 3, 4
- Van Oudenaarden, Alexander12, 8
- Dowsett, Mitchell13
- Jones, Robin L.14, 13
- Reis-Filho, Jorge15, 13
- Gascon, Pere1
- Gönen, Mithat15
- Michor, Franziska5, 4
- Polyak, Kornelia16, 17, 2, 3, 4
- Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)
- 1. Institut d'Investigacions Biomediques, Barcelona (Spain)
- 2. Harvard Medical School, Boston, MA (United States)
- 3. Brigham and Women's Hospital, Boston, MA (United States)
- 4. Dana-Farber Cancer Institute, Boston, MA (United States)
- 5. Harvard School of Public Health, Boston, MA (United States)
- 6. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
- 7. Weizmann Institute of Science, Rehovot (Israel)
- 8. MIT (Massachusetts Inst. of Technology), Cambridge, MA (United States)
- 9. Oslo Univ. Hospital, Oslo (Norway)
- 10. Univ. of Oslo, Oslo (Norway)
- 11. Oslo Univ. Hospital Radiumhospitalet, Oslo (Norway)
- 12. Royal Netherlands Academy of Arts and Sciences and Univ. Medical Center Utrecht, Utrecht (Netherlands)
- 13. The Royal Marsden Hospital, London (United Kingdom)
- 14. Seattle Cancer Care Alliance, Seattle, WA (United States)
- 15. Memorial Sloan-Kettering Cancer Center, New York, NY (United States)
- 16. Broad Institute, Cambridge, MA (United States)
- 17. Harvard Stem Cell Institute, Cambridge, MA (United States)
Description
Cancer therapy exerts a strong selection pressure that shapes tumor evolution, yet our knowledge of how tumors change during treatment is limited. Here, we report the analysis of cellular heterogeneity for genetic and phenotypic features and their spatial distribution in breast tumors pre- and post-neoadjuvant chemotherapy. We found that intratumor genetic diversity was tumor-subtype specific, and it did not change during treatment in tumors with partial or no response. However, lower pretreatment genetic diversity was significantly associated with pathologic complete response. In contrast, phenotypic diversity was different between pre- and post-treatment samples. We also observed significant changes in the spatial distribution of cells with distinct genetic and phenotypic features. We used these experimental data to develop a stochastic computational model to infer tumor growth patterns and evolutionary dynamics. Our results highlight the importance of integrated analysis of genotypes and phenotypes of single cells in intact tissues to predict tumor evolution
Availability note (English)
Available from: DOI:10.1016/j.celrep.2013.12.041 ; DOE Accepted Manuscript full text, or the publishers Best Available Version will be available free of charge after the embargo period from OSTI using http://www.osti.gov/pages/biblio/1201672Additional details
Identifiers
Publishing Information
- Journal Title
- Cell Reports
- Journal Volume
- 6
- Journal Issue
- 3
- Journal Page Range
- p. 514-527
- ISSN
- 2211-1247
INIS
- Country of Publication
- Netherlands
- Country of Input or Organization
- United States
- INIS RN
- 47075053
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CHEMOTHERAPY; GENETIC VARIABILITY; GENOTYPE; MAMMARY GLANDS; NEOPLASMS; PHENOTYPE; SPATIAL DISTRIBUTION; STOCHASTIC PROCESSES
- Descriptors DEC
- BIOLOGICAL VARIABILITY; BODY; DISEASES; DISTRIBUTION; GLANDS; MEDICINE; ORGANS; THERAPY
Optional Information
- Funding organization
- USDOE (United States)
- Secondary number(s)
- OSTIID--1201672